|
| 37174000 | Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients. | | 2023 |
| 36104079 | Impact of substage and histologic type in stage I ovarian carcinoma survival: a multicenter retrospective observational study. | International Journal of Gynecological Cancer | 2023 |
| 36127525 | Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database. | Arch Gynecol Obstet | 2023 |
| 37839314 | Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study. | | 2023 |
| 37890354 | Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth? | | 2023 |
| 37862791 | Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100. | | 2023 |
| 36716415 | Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. | JCO Precis Oncol | 2023 |
| 36572991 | CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. | Cancer | 2023 |
| 36759002 | Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence. | | 2023 |
| 37001891 | Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group. | Int J Gynecol Cancer | 2023 |
| 35130283 | Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer. | PLoS ONE | 2022 |
| 35524184 | Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial. | BMC Cancer | 2022 |
| 35383091 | Ten years of live surgical broadcast at Charité-MAYO conferences (2010-2019): a systematic evaluation of the surgical outcome. | International Journal of Gynecological Cancer | 2022 |
| 36273925 | Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis. | Gynecologic Oncology | 2022 |
| 36001383 | Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant. | Clin Cancer Res | 2022 |
| 35738917 | Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer. | Gynecologic Oncology | 2022 |
| 35361918 | Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. | British Journal of Cancer | 2022 |
| 35361918 | Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. | British Journal of Cancer | 2022 |
| 36191839 | Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling. | J Mol Diagn | 2022 |
| 35320115 | Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation. | International Journal of Gynecological Cancer | 2022 |
| 34923575 | Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC). | British Journal of Cancer | 2022 |
| 35267497 | Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. | Cancers (Basel) | 2022 |
| 35235736 | Cytoreductive Surgery for Relapsed Ovarian Cancer. Reply. | New England Journal of Medicine | 2022 |
| 34782936 | MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. | Virchows Arch | 2022 |
| 34724570 | The role of factor XIII in surgery for advanced stage of epithelial ovarian cancer. | Archives of Gynecology and Obstetrics | 2022 |
| 34897700 | Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. | J Pathol | 2022 |
| 35017033 | Homologous recombination deficiency testing in first-line ovarian cancer. | Annals of Oncology | 2022 |
| 34874631 | Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. | N Engl J Med | 2021 |
| 34287678 | The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group. | Arch Gynecol Obstet | 2021 |
| 33743851 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. | Lancet Oncology, The | 2021 |
| 33794043 | ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors. | Ultrasound Obstet Gynecol | 2021 |
| 34162658 | Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 34112736 | ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. | Int J Gynecol Cancer | 2021 |
| 33675937 | The systemic treatment of recurrent ovarian cancer revisited. | Annals of Oncology | 2021 |
| 34107646 | ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours. | Facts Views Vis Obgyn | 2021 |
| 33661392 | Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients. | Archives of Gynecology and Obstetrics | 2021 |
| 33917079 | A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer. | Cancers (Basel) | 2021 |
| 33710393 | Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience. | Archives of Gynecology and Obstetrics | 2021 |
| 33168305 | Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer? | Gynecologic Oncology | 2021 |
| 34565600 | Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data. | Gynecologic Oncology | 2021 |
| 34725245 | Some thoughts about surgery in ovarian cancer 2021. | International Journal of Gynecological Cancer | 2021 |
| 34720807 | Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet. | Breast Care | 2021 |
| 35008332 | Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer-Impact for Diagnosis and Treatment Monitoring. | Cancers | 2021 |
| 34593530 | Ovarian Cancer-Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. | Clin Cancer Res | 2021 |
| 34417253 | Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al. | International Journal of Gynecological Cancer | 2021 |
| 31381147 | Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. | Int J Cancer | 2020 |
| 32139438 | Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). | International Journal of Gynecological Cancer | 2020 |
| 32360491 | Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma. | Hum Pathol | 2020 |
| 32306054 | Feasibility of internal inguinoperitoneal drainage after inguinofemoral lymphadenectomy in vulvar cancer. | Archives of Gynecology and Obstetrics | 2020 |
| 32305099 | Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. | Lancet Oncol | 2020 |